Literature DB >> 33592559

Cessation classification likelihood increases with higher expired-air carbon monoxide cutoffs: a meta-analysis.

Joshua L Karelitz1, Erin A McClure2, Caitlin Wolford-Clevenger3, Lauren R Pacek4, Karen L Cropsey3.   

Abstract

BACKGROUND: Expired-air carbon monoxide (CO) is commonly used to biochemically verify smoking status. The CO cutoff and CO monitor brand may affect the probability of classifying smokers as abstinent, thus influencing conclusions about the efficacy of cessation trials. No systematic reviews have tested this hypothesis. Therefore, we performed a meta-analysis examining whether the likelihood of smoking cessation classification varied due to CO cutoff and monitor brand.
METHODS: Eligible studies (k = 122) longitudinally assessed CO-verified cessation in adult smokers in randomized trials. Primary meta-regressions separately assessed differences in quit classification likelihood due to continuous and categorical CO cutoffs (Low, 3-4 parts per million [ppm]; [SRNT] Recommended, 5-6 ppm; Moderate, 7-8 ppm; and High, 9-10 ppm); exploratory analyses compared likelihood outcomes between monitor brands: Bedfont and Vitalograph.
RESULTS: The likelihood of quit classification increased 18% with each 1 ppm increase above the lowest cutoff (3 ppm). Odds of classification as quit significantly increased between each cutoff category and High: 261% increase from Low; 162% increase from Recommended; and 150% increase from Moderate. There were no differences in cessation classification between monitor brands.
CONCLUSIONS: As expected, higher CO cutoffs were associated with greater likelihood of cessation classification. The lack of CO monitor brand differences may have been due to model-level variance not able to be followed up in the present dataset. Researchers are advised to report outcomes using a range of cutoffs-including the recommended range (5-6 ppm)-and the CO monitor brand/model used. Using higher CO cutoffs significantly increases likelihood of quit classification, possibly artificially elevating treatment strategies.
Copyright © 2021 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Bioverification; Expired-air carbon monoxide; Meta-analysis; Smoking cessation

Mesh:

Substances:

Year:  2021        PMID: 33592559      PMCID: PMC8026538          DOI: 10.1016/j.drugalcdep.2021.108570

Source DB:  PubMed          Journal:  Drug Alcohol Depend        ISSN: 0376-8716            Impact factor:   4.492


  141 in total

1.  Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis.

Authors:  S Duval; R Tweedie
Journal:  Biometrics       Date:  2000-06       Impact factor: 2.571

2.  Electronic cigarettes for smoking cessation: a randomised controlled trial.

Authors:  Christopher Bullen; Colin Howe; Murray Laugesen; Hayden McRobbie; Varsha Parag; Jonathan Williman; Natalie Walker
Journal:  Lancet       Date:  2013-09-09       Impact factor: 79.321

3.  Varenicline efficacy and safety among methadone maintained smokers: a randomized placebo-controlled trial.

Authors:  Shadi Nahvi; Yuming Ning; Kate S Segal; Kimber P Richter; Julia H Arnsten
Journal:  Addiction       Date:  2014-06-27       Impact factor: 6.526

4.  Effects of varenicline on smoking cessation in patients with mild to moderate COPD: a randomized controlled trial.

Authors:  Donald P Tashkin; Stephen Rennard; J Taylor Hays; Wendy Ma; David Lawrence; Theodore C Lee
Journal:  Chest       Date:  2010-09-23       Impact factor: 9.410

5.  It is feasible and effective to help patients with severe mental disorders to quit smoking: An ecological pragmatic clinical trial with transdermal nicotine patches and varenicline.

Authors:  Maria P Garcia-Portilla; Leticia Garcia-Alvarez; Fernando Sarramea; Gonzalo Galvan; Eva Diaz-Mesa; Teresa Bobes-Bascaran; Susana Al-Halabi; Edorta Elizagarate; Celso Iglesias; Pilar A Saiz Martínez; Julio Bobes
Journal:  Schizophr Res       Date:  2016-05-26       Impact factor: 4.939

6.  Varenicline for smoking cessation in bipolar disorder: a randomized, double-blind, placebo-controlled study.

Authors:  K N Roy Chengappa; Kenneth A Perkins; Jaspreet S Brar; Patricia J Schlicht; Scott R Turkin; Michelle L Hetrick; Michele D Levine; Tony P George
Journal:  J Clin Psychiatry       Date:  2014-07       Impact factor: 4.384

7.  Adapting smoking cessation treatment according to initial response to precessation nicotine patch.

Authors:  Jed E Rose; Frédérique M Behm
Journal:  Am J Psychiatry       Date:  2013-08       Impact factor: 18.112

8.  Combining varenicline and nicotine patches: a randomized controlled trial study in smoking cessation.

Authors:  Josep M Ramon; Sergio Morchon; Antoni Baena; Cristina Masuet-Aumatell
Journal:  BMC Med       Date:  2014-10-08       Impact factor: 8.775

9.  Randomized trial of nicotine replacement therapy (NRT), bupropion and NRT plus bupropion for smoking cessation: effectiveness in clinical practice.

Authors:  John Stapleton; Robert West; Peter Hajek; Jenny Wheeler; Eleni Vangeli; Zeinab Abdi; Colin O'Gara; Hayden McRobbie; Kirsty Humphrey; Rachel Ali; John Strang; Gay Sutherland
Journal:  Addiction       Date:  2013-08-28       Impact factor: 6.526

10.  Extending varenicline preloading to 6 weeks facilitates smoking cessation: A single-site, randomised controlled trial.

Authors:  Abraham Bohadana; Yossi Freier-Dror; Vardit Peles; Polina Babai; Gabriel Izbicki
Journal:  EClinicalMedicine       Date:  2020-02-03
View more
  1 in total

1.  Promotion of Smoking Cessation Using the Transtheoretical Model: Short-Term and Long-Term Effectiveness for Workers in Coastal Central Taiwan.

Authors:  Ming-Feng Tseng; Chia-Chen Huang; Stella Chin-Shaw Tsai; Ming-Daw Tsay; Yu-Kang Chang; Chun-Lin Juan; Fang-Chi Hsu; Ruey-Hong Wong
Journal:  Tob Use Insights       Date:  2022-06-02
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.